These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 342824)

  • 1. Long term effects of chemoprophylaxis among contacts of lepromatous cases. Results of 8 1/2 years follow-up.
    Noordeen SK
    Lepr India; 1977 Oct; 49(4):504-9. PubMed ID: 342824
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoprophylaxis among contacts of non-lepromatous leprosy.
    Noordeen SK; Neelan PN
    Lepr India; 1976 Oct; 48(4 Suppl):635-42. PubMed ID: 800232
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemoprophylaxis in leprosy.
    Br Med J; 1966 May; 1(5498):1252. PubMed ID: 5328408
    [No Abstract]   [Full Text] [Related]  

  • 4. Limited duration acedapsone prophylaxis in leprosy.
    Neelan PN; Sirumban P; Sivaprasad N
    Indian J Lepr; 1986; 58(2):251-6. PubMed ID: 3543161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DDS chemoprophylaxis for leprosy in children at Culion Sanitarium Palawan, Philippines.
    Lara CB
    Acta Leprol; 1978; (70):35-58. PubMed ID: 104537
    [No Abstract]   [Full Text] [Related]  

  • 6. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8-10 years.
    Sharma P; Mukherjee R; Talwar GP; Sarathchandra KG; Walia R; Parida SK; Pandey RM; Rani R; Kar H; Mukherjee A; Katoch K; Benara SK; Singh T; Singh P
    Lepr Rev; 2005 Jun; 76(2):127-43. PubMed ID: 16038246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprophylaxis against leprosy with acedapsone. An interim report.
    Noordeen SK; Neelan PN; Munaf A
    Lepr India; 1980 Jan; 52(1):97-103. PubMed ID: 6991817
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of household contacts of leprosy patients.
    Filice GA; Fraser DW
    Ann Intern Med; 1978 Apr; 88(4):538-42. PubMed ID: 345906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended studies on chemoprophylaxis against leprosy.
    Noordeen SK; Neelan PN
    Indian J Med Res; 1978 Apr; 67():515-27. PubMed ID: 355134
    [No Abstract]   [Full Text] [Related]  

  • 11. Controlled comparison of therapeutic effects of DDS in combination with daily or once-monthly rifampicin in patients with lepromatous leprosy.
    Ghosh S; McDougall AC; Hazra SK; Yawalkar SJ
    Indian J Dermatol; 1981 Oct; 26(4):1-6. PubMed ID: 6754585
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic effects of adding rimactane (rifampicin) 450 milligrams daily or 1200 milligrams once monthly in a single dose to dapsone 50 milligrams daily in patients with lepromatous leprosy.
    Languillon J; Yawalkar SJ; McDougall AC
    Int J Lepr Other Mycobact Dis; 1979 Mar; 47(1):37-43. PubMed ID: 376454
    [No Abstract]   [Full Text] [Related]  

  • 13. Introductory rifampicin therapy in lepromatous leprosy: a six month follow-up study.
    Girdhar BK; Ramu G; Sreevatsa ; Desikan KV
    Lepr India; 1978 Jul; 50(3):363-70. PubMed ID: 359925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutic trials in leprosy. 4. Dapsone (DDS) in low dosage in the treatment of lepromatous leprosy. A demonstration pilot study.
    Pettit JH; Rees RJ
    Int J Lepr Other Mycobact Dis; 1967; 35(2):140-8. PubMed ID: 5338958
    [No Abstract]   [Full Text] [Related]  

  • 15. Leprosy control in Shandong Province, China, 1955-1983; some epidemiological features.
    Li HY; Pan YL; Wang Y
    Int J Lepr Other Mycobact Dis; 1985 Mar; 53(1):79-85. PubMed ID: 3998564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.
    Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study on transmission and a trial of chemoprophylaxis in contacts of leprosy patients: design, methodology and recruitment findings of COLEP.
    Moet FJ; Oskam L; Faber R; Pahan D; Richardus JH
    Lepr Rev; 2004 Dec; 75(4):376-88. PubMed ID: 15682975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A statistical analysis of two chemotherapy trials in lepromatous leprosy. I. The response to therapy as measured by inoculation of mice.
    Am J Trop Med Hyg; 1978 Sep; 27(5):1005-14. PubMed ID: 362950
    [No Abstract]   [Full Text] [Related]  

  • 19. Repository acedapsone in leprosy chemoprophylaxis and treatment.
    Sloan NR; Worth RM; Jano B; Fasal P; Shepard CC
    Lancet; 1971 Sep; 2(7723):525-6. PubMed ID: 4105668
    [No Abstract]   [Full Text] [Related]  

  • 20. Prospective immunological follow-up in household contacts of Mexican leprosy patients.
    Amezcua ME; Escobar-Gutiérrez A; Barba-Rubio J; Cázares JV; Mayén E; Chávez-Núñez M; Peña RC; Rodríguez R; Pastén S
    Int J Lepr Other Mycobact Dis; 1990 Dec; 58(4):651-9. PubMed ID: 2280115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.